Get the latest news, insights, and market updates on CTKB (Cytek Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Global Healthcare Conference in Palm Beach, FLParticipating in investor 1x1 meetings on Tuesday, November 11, 2025 Stephens NASH25 Investment Conference in Nashville, TNFireside chat on November 19, 2025, at 9:00 a.m. Pacific Time /12:00 p.m. Eastern Time Piper Sandler 37t Nov 6, 2025 - $CTKB
Cytek Biosciences Reports Third Quarter 2025 Financial Results
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 20 Nov 5, 2025 - $CTKB
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants Cytek research initiative Cytek is supporting ISAC in a shared mission to extend flow cytometry reach worldwide. In this effort, Cytek has launched a two-part research initiative. In the first phase of the program, Cytek is awarding a three-laser Cytek Northern Lights™ flow cytometer. In the second phase, Cytek plans to launch a grant program to fund eligible research Oct 29, 2025 - $CTKB
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investo Oct 22, 2025 - $CTKB
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
Cytek European Facility Cytek’s new facility in Amsterdam, The Netherlands, expands the company’s capacity to meet the growing demand for comprehensive cell analysis solutions. FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam’s Life Sciences Dist Oct 15, 2025 - $CTKB
AC Immune Leads Our Trio Of Promising Penny Stocks
The U.S. stock market has been on a positive streak, with major indices like the Dow and S&P 500 setting new records despite concerns over a government shutdown. In such an environment, investors often look for opportunities that balance potential growth with financial stability. Penny stocks, while historically seen as high-risk investments due to their association with smaller or newer companies, can still offer significant value when backed by strong financials and clear growth paths. This... Oct 2, 2025 - $CTKB
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?
Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Sep 24, 2025 - $CTKB
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and DiscoveryFREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced, high-parameter solutions at two notable industry events later this month: the European Society for Clinical Cell Analysis (ESCCA) 2025 Conference and ICCS 2025, the 40th Sep 10, 2025 - $CTKB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple